Moderna stock weighs profit return against higher 2026 outlook

Moderna stock is trading after the biotechnology company returned to quarterly GAAP profit and lifted its full-year revenue outlook. Moderna published the results on Friday, November 6, while its investor-relations review on the company website highlighted stronger sales, lower cash costs and a higher projected cash balance.

Moderna stock traded at 229.28 euros on Lang & Schwarz at 16:10 CET on Tuesday, November 10, down 4.78 percent from the 240.78-euro quote in our report published at 13:59 CET the same day. The move is a separate market observation and does not by itself establish why the share price changed.

Quarterly Profit Changes the Setup

Third-quarter revenue rose 29 percent year over year to 1.3 billion US dollars. Moderna reported 162 million US dollars in net income, compared with a 200 million US dollar loss in the year-earlier quarter, while diluted earnings reached 0.38 US dollars per share.

According to CNBC, international COVID-19 vaccine sales and deliveries under long-term government partnerships supported the quarter. US revenue was 780 million US dollars, while international revenue reached 533 million US dollars.

Higher Guidance Tests Durability

Management now expects total 2026 revenue growth of 15 percent to 25 percent, compared with a previous outlook of up to 10 percent. Moderna also expects year-end cash and investments of 8.1 billion to 8.3 billion US dollars, above its earlier range of 4.7 billion to 5.2 billion US dollars.

The improved framework raises the execution bar for the remaining quarters. The company said cash costs fell 10 percent to 1.0 billion US dollars in the third quarter and that it expects its first full year of revenue growth since 2022.

Pipeline Broadens the Next Phase

Moderna and Merck reported positive Phase 3 results for intismeran in melanoma, while the company also highlighted US approval for its standalone flu vaccine. Moderna expects data by year-end from its pivotal study of mRNA-3927 in propionic acidemia and plans to present initial mRNA-2808 data at the American Society of Hematology meeting from December 12 to 15, 2026.

The S&P 500 remains the relevant broader-market backdrop for US-listed biotechnology shares.

More earnings execution and clinical progress will determine whether Moderna can turn the improved outlook into durable growth. More news and analyses on Moderna stock remain focused on that transition.